MX2024005076A - Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal. - Google Patents
Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal.Info
- Publication number
- MX2024005076A MX2024005076A MX2024005076A MX2024005076A MX2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A MX 2024005076 A MX2024005076 A MX 2024005076A
- Authority
- MX
- Mexico
- Prior art keywords
- coated
- oral formulation
- prophylaxis
- treatment
- intestinal fibrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/079584 WO2023072368A1 (en) | 2021-10-25 | 2021-10-25 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
| PCT/EP2022/079666 WO2023072878A1 (en) | 2021-10-25 | 2022-10-24 | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005076A true MX2024005076A (es) | 2024-05-13 |
Family
ID=78536154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005076A MX2024005076A (es) | 2021-10-25 | 2022-10-24 | Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal. |
Country Status (11)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297020A (en) | 2020-04-24 | 2022-12-01 | Dr Falk Pharma Gmbh | A systemic preparation of a pyridonone derivative related to tg2 |
| HRP20231072T1 (hr) | 2020-04-24 | 2023-12-22 | Dr. Falk Pharma Gmbh | Sustavna formulacija derivata piridinona za celijakiju |
| WO2025153465A1 (en) * | 2024-01-15 | 2025-07-24 | UCB Biopharma SRL | Method for the treatment of fibrotic-related disorder associated to ibd |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| EP2687511A1 (de) * | 2012-07-17 | 2014-01-22 | Zedira GmbH | Pyridinonderivate als Gewebetransglutaminaseinhibitoren |
-
2021
- 2021-10-25 WO PCT/EP2021/079584 patent/WO2023072368A1/en not_active Ceased
-
2022
- 2022-10-24 CN CN202280071095.9A patent/CN118234489A/zh active Pending
- 2022-10-24 JP JP2024524678A patent/JP2024536609A/ja active Pending
- 2022-10-24 US US18/704,228 patent/US20250041228A1/en active Pending
- 2022-10-24 CA CA3230682A patent/CA3230682A1/en active Pending
- 2022-10-24 EP EP22809386.0A patent/EP4312994A1/en active Pending
- 2022-10-24 MX MX2024005076A patent/MX2024005076A/es unknown
- 2022-10-24 KR KR1020247017206A patent/KR20240093898A/ko active Pending
- 2022-10-24 AU AU2022374695A patent/AU2022374695A1/en active Pending
- 2022-10-24 IL IL312176A patent/IL312176A/en unknown
- 2022-10-24 WO PCT/EP2022/079666 patent/WO2023072878A1/en not_active Ceased
-
2024
- 2024-04-10 ZA ZA2024/02786A patent/ZA202402786B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL312176A (en) | 2024-06-01 |
| JP2024536609A (ja) | 2024-10-04 |
| KR20240093898A (ko) | 2024-06-24 |
| US20250041228A1 (en) | 2025-02-06 |
| WO2023072368A1 (en) | 2023-05-04 |
| WO2023072878A1 (en) | 2023-05-04 |
| CN118234489A (zh) | 2024-06-21 |
| EP4312994A1 (en) | 2024-02-07 |
| AU2022374695A1 (en) | 2024-03-21 |
| CA3230682A1 (en) | 2023-05-04 |
| ZA202402786B (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2593582T3 (es) | Formulación de comprimido recubierto y método | |
| CN1404389B (zh) | 时控脉冲给药系统 | |
| CN101711752B (zh) | 一种苯并异噁唑类衍生物的控释制剂及其制备方法 | |
| ZA202402786B (en) | Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis | |
| KR20170033358A (ko) | 브루톤 티로신 키나아제 저해제의 신규한 제제 | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2017128614A5 (cg-RX-API-DMAC10.html) | ||
| CN104288774B (zh) | 一种肠溶包衣、富马酸二甲酯肠溶制剂及其制备方法 | |
| RS56019B1 (sr) | Premazana farmaceutska kompozicija koja sadrži regorafenib | |
| KR102024699B1 (ko) | 클로피도그렐 및 아스피린을 포함하는 복합제제 | |
| JP2019509345A5 (cg-RX-API-DMAC10.html) | ||
| CN101428005A (zh) | 泮托拉唑及其钠盐肠溶缓释微丸制剂 | |
| CN101496789A (zh) | 西他沙星缓释微丸及其制备方法 | |
| EP2533766B1 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| CN105025883A (zh) | 右哌甲酯或其盐的调节释放的药物组合物 | |
| CN105640909B (zh) | 一种含有达比加群酯的药用组合物 | |
| WO2015085739A1 (zh) | 一种多层固体药物剂型 | |
| RS66154B1 (sr) | Formulacije stimulansa sa tropulsnim oslobađanjem | |
| ES2900975T3 (es) | Preparación farmacéutica oral con revestimiento entérico que comprende fumarato de dimetilo | |
| CN104856971B (zh) | 一种脉冲双释放制剂及其制备方法与应用 | |
| WO2012150246A1 (de) | Arzneiform zur gezielten freigabe von wirkstoffen | |
| CN1311824C (zh) | 奥美拉唑肠溶微粒制剂及制备方法 | |
| Sonawane et al. | Formulation aspects and effect of critical factors for designing extended release pellets: an updated review | |
| CN103127004B (zh) | 一种藻酸双酯钠缓释颗粒及其制备方法 | |
| CA3007483C (en) | Process for preparation of an enteric coated granulate comprising dimethyl fumarate |